

Phase II trial: ETH47-201

Submission date 23/05/2025	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/06/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 03/06/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Contact information

Type(s)

Principal investigator

Contact name

Prof Onn Min Kon

Contact details

Imperial College Healthcare NHS Trust
South Wharf Road
London
United Kingdom
W2 1NY
+44 (0)203 312 1344
onn.kon@nhs.net

Type(s)

Scientific

Contact name

Dr Michael Edwards

Contact details

2 Royal College Street
London
United Kingdom

NW1 0NH
+44 (0)20 7554 5855
info@virtus-rr.com

Type(s)

Public

Contact name

Ms Tika Endeladze

Contact details

2 Royal College Street
London
United Kingdom
NW1 0NH
+44 (0)20 7554 5855
info@virtus-rr.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1011224

Protocol serial number

ETH47-201

Study information

Scientific Title

Phase II trial: ETH47-201

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 14/02/2025, Wales 3 REC (Wales Research Ethics Committee 3, Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road East, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922 941107; Wales.REC3@wales.nhs.uk), ref: 25/WA/0013

Study design

Phase II double-blind randomized placebo-controlled study in 50 volunteers with asthma

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Completion date

12/05/2026

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended

Date of first enrolment

09/06/2025

Date of final enrolment

12/05/2026

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre**Imperial College Respiratory Research Unit**

Imperial College Healthcare NHS Trust

Mint Wing

South Wharf Road

St Mary's Hospital

London

United Kingdom

W2 1NY

Sponsor information**Organisation**

Ethris GmbH

Funder(s)

Funder type

Industry

Funder Name

Ethris GmbH

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials

IPD sharing plan summary

Not expected to be made available